drugset / Trial / NCT05606107
To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks
Phase 4
Unknown
230 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Jiaxing Hospital of T.C.M · collabJinhua Municipal Central Hospital · collabSAHZU.CHANGXING CAMPUS · collabShaoxing People's Hospital · collabZhuji People's Hospital of Zhejiang Province · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Glucocorticoids are effective in the treatment of rheumatoid arthritis, but long-term use of glucocorticoids has many side effects. Tofacitinib is a new small-molecule drug targeting JAK, which has been found to act quickly. The aim of this clinical trial was to investigate the efficacy and safety of tofacitinib and low-dose glucocorticoids in inducing remission in patients with rheumatoid arthritis with moderate to high disease activity.
Timeline
- Start
- 2022-05-20
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tofacitinib | Small molecule | — | — |